Business Wire

Tradeweb Joins Climate Bonds Initiative Partners Program

20.4.2021 16:00:00 EEST | Business Wire | Press release

Share

Tradeweb Markets Inc. (Nasdaq: TW), a leading, global operator of electronic marketplaces for rates, credit, equities and money markets, today announced it has joined the Climate Bonds Initiative’s Partners Program, a global movement seeking to mobilise bond markets for climate change solutions. Climate Bonds Initiative is an international, investor-focused not-for-profit organisation, promoting investment in projects and assets necessary for a rapid transition to a low carbon and climate resilient economy.

The Climate Bonds Standard and Certification Scheme is a labelling scheme for bonds, loans and other debt instruments. The rigorous scientific criteria ensure consistency with the goals of the Paris Climate Agreement. The Scheme is used globally by bond issuers, governments, investors and the financial markets to prioritize investments, which genuinely contribute to addressing climate change. The Climate Bonds Initiative has been tracking the green labelled market since 2009. By partnering with Climate Bonds, Tradeweb aims to promote the visibility and accessibility of green bond trading activity across a wide range of asset classes, and leverage Climate Bonds data to provide transparency and clarity around our Green Bond Trading volumes.

“As one of the largest green bond marketplaces in the world, Tradeweb is proud to become an official Partner of the Climate Bonds Initiative,” said Lee Olesky, CEO of Tradeweb Markets. “A sustainable global financial system is no longer optional, it’s a necessity, so we need to leverage available ESG data and research to promote transparency and integrity in Green and Social bond trading.”

In 2020, Climate Bonds screened Green bonds accounted for $79 billion (bn) of the total $82bn in Green bond trading volume executed on Tradeweb. This represents an increase of 65% in screened Green Bond Trading from 2019. The remaining $3bn in volume accounted for trading of non-aligned Green debt.

2020 Green Bond Trading Highlights:

  • $56.4 billion in cash rates led by global government bonds
    • European government bonds ($43.9bn) and Other* Global bonds ($12.0bn)
  • $22.7 billion in global cash credit led by U.S. and European corporate credit
    • European Credit ($15.5bn) and US High-Grade Credit ($5.7bn)

“Green investment is expanding in depth and diversity, and Tradeweb occupies a significant position in the market,” said Sean Kidney, CEO Climate Bonds Initiative. “We welcome them to our Partners Program and look forward to working cooperatively in bringing enhanced information and transparency available to institutional investors.”

“Tradeweb’s multi-asset offering gives us a unique vantage point into ESG trading activity,” added Simon Maisey, Global Head of Corporate Development at Tradeweb. “We remain focused on powering clients’ sustainable investment strategies with solutions that efficiently identify and highlight green bonds on our platform, ultimately providing them with a robust view of activity across a broad range of asset classes.”

As a result of the incredible growth green and sustainable markets have seen in recent years, a broadening number of government entities and corporates are now engaging with investors on ESG-aligned initiatives, while making an environmental or social impact. Tradeweb’s collaboration with the Climate Bonds Initiative helps market participants gain valuable insight into this trading activity, allowing a clearer view on how green and other sustainable securities trade in relation to their non-green counterparts. Tradeweb is committed to developing tools to identify green bonds across a wide range of asset classes, with green bond flags already available for European Government bonds and Global Credit.

* Other Global Bonds: AUD, NZD, JPY, CAD Government bonds, Covered bonds, U.S. Agencies and other supranational.

About Tradeweb Markets

Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 40 products to clients in the institutional, wholesale and retail markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves approximately 2,500 clients in more than 65 countries. On average, Tradeweb facilitated more than $ 830 billion in notional value traded per day over the past four fiscal quarters. For more information, please go to www.tradeweb.com.

About the Climate Bonds Initiative: Climate Bonds Initiative is an investor-focused not-for-profit, promoting large-scale investment in the low carbon economy. Climate Bonds undertakes advocacy and outreach to inform and stimulate the market, provides policy models and government advice, market data and analysis, and administers an international Standard & Certification Scheme for best practice in green bonds issuance. For more information, please visit www.climatebonds.net.

About Climate Bonds Green Bond Database & Methodology: The Methodology V1.1 outline processes and criteria to define green bonds, green loans, green sukuk and other similar labelled debt instruments as eligible for inclusion in the Green Bond Database.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws. Statements related to, among other things, our outlook and future performance, the industry and markets in which we operate, our expectations, beliefs, plans, strategies, objectives, prospects and assumptions and future events are forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed under the heading “Risk Factors” in documents of Tradeweb Markets Inc. on file with or furnished to the SEC, may cause our actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements contained in this release are not guarantees of future performance and our actual results of operations, financial condition or liquidity, and the development of the industry and markets in which we operate, may differ materially from the forward-looking statements contained in this release. In addition, even if our results of operations, financial condition or liquidity, and events in the industry and markets in which we operate, are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods.

Any forward-looking statement that we make in this release speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Contact
Ashley Serrao
+ 1 646 430 6027
Ashley.Serrao@Tradeweb.com

Media Contacts
Susan Bennett
+44 7787 666432
Susan.Bennett@tradeweb.com

Angeliki Kallipoliti
+44 7824 327073
Angeliki.Kallipoliti@tradeweb.com

Daniel Noonan
+1 646 767 4677
Daniel.Noonan@Tradeweb.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye